Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellSource CoTSE:4880 +3.54%70 Debt-to-EBITDA is 0.06 as of Apr. 2026, which is 20% above its 10-year median of 0.05. GuruFocus rates TSE:4880 with a GF Score™ of 70/100 and a GF Value™ of 円777.90 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 309 Biotechnology companies, CellSource Co ranks better than 87.06% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for CellSource Co's Debt-to-EBITDA or its related term are showing as below:
TSE:4880'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0.05 Max: 0.18
Current: 0.07
During the past 9 years, the highest Debt-to-EBITDA Ratio of CellSource Co was 0.18. The lowest was 0.00. And the median was 0.05.
TSE:4880's Debt-to-EBITDA is ranked better than 87.06% of 309
companies
in the Biotechnology industry
Industry Median: 1.39
vs TSE:4880: 0.07
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
CellSource Co Debt-to-EBITDA Related Terms
CellSource Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for CellSource Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4880 vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, CellSource Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CellSource Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Apr. 2026) EBITDA data.
CellSource Co (TSE:4880) has a Debt-to-EBITDA of 0.06 as of Apr. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CellSource Co. This is 20% above median its historical median of 0.05. According to the industry distribution chart, CellSource Co ranks #40 out of 309 companies in the Biotechnology industry, placing it in the top 12.9%.
Is CellSource Co's Debt-to-EBITDA too high?
CellSource Co's current Debt-to-EBITDA of 0.06 is 20% above median its 10-year median of 0.05. The Biotechnology industry median Debt-to-EBITDA is 1.39. CellSource Co's value of 0.06 is 95.7% below this industry median. Based on the distribution chart, CellSource Co ranks #40 out of 309 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CellSource Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #40 out of 309 companies for Debt-to-EBITDA. This places CellSource Co in the top 13% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.39. CellSource Co's value of 0.06 is 95.7% below this benchmark. While the company's 10-year median is 0.05 vs. the industry median of 1.39, CellSource Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.39, based on 309 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellSource Co's current Debt-to-EBITDA of 0.06 is 95.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CellSource Co. For the Biotechnology industry, the median Debt-to-EBITDA is 1.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellSource Co's current Debt-to-EBITDA is 0.06, which is 20% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円777.90, compared to a current price of 円351.00 — trading 54.9% below its estimated fair value. The current Debt-to-EBITDA is 0.06, which is 20% above median its 10-year median of 0.05 and 95.7% below the Biotechnology industry median of 1.39. CellSource Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current Debt-to-EBITDA is 0.06 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円351.00 is trading 54.9% below its estimated GF Value™ of 円777.90.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
Debt-to-EBITDA: 0.06 (20% above median its 10-year median of 0.05)
GF Value™: 円777.90 vs. price of 円351.00 (54.9% below fair value)
Industry Position: 95.7% below the Biotechnology median (#40 of 309)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
70GF Score
Get the complete analysis for TSE:4880
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
